Sustained B-Cell Depletion Controls Lymphoproliferative Bowel Disease in AID Deficiency
Long-term off-label anti-CD20 therapy effectively manages persistent, benign lymphoproliferative bowel disease in a patient with an activation-induced cytidine deaminase deficiency.

